Ricevi le ultime notizie sulle azioni Revelation Biosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di REVB

Ultime notizie per

Revelation Biosciences

Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences Inc

Press Releases

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

News

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Offerings

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

REVB

Aditxt

Ainos

Apollomics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Azitra

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

BioVie

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

ETHZilla

GRI Bio

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Liminatus Pharma

Lixte Biotechnology Holdings, Inc. - Warrants

Lixte Biotechnology

Medicus Pharma

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Revolution Medicines

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Silexion Therapeutics

Alaunos Therapeutics, Inc. - Common Stock

Comments

Revelation Biosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO